Central Drugs Standard Control Organization (CDSCO) issued a circular dated 3rd September 2025, referencing the 314th RCGM meeting. It announces that Institutional Biosafety Committee (IBSC) approvals will be accepted for submitting Form CT-10 to seek permission for manufacturing test items for examination, test, and analysis specifically for Category I and II genetically engineered experiments. This streamlines regulatory procedures for biopharmaceutical manufacturers conducting R&D under the 2017 Recombinant DNA Guidelines.

